PLX.TA - Protalix BioTherapeutics, Inc.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
158.50
-1.50 (-0.94%)
At close: 5:24PM IDT
Stock chart is not supported by your current browser
Previous Close160.00
Open160.00
Bid158.30 x 128000
Ask158.50 x 209400
Day's Range157.50 - 159.70
52 Week Range143.60 - 325.00
Volume53,477
Avg. Volume204,799
Market Cap222.778M
Beta1.15
PE Ratio (TTM)N/A
EPS (TTM)-0.26
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire2 months ago

    Protalix BioTherapeutics Announces Additional Positive Results from Final Analysis of the Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis

    Mucosal Improvement Observed in 61% of the Patients and 33% achieved Mucosal Healing. Clinical Responses Observed in 67% of the Patients and Clinical Remission Observed in 28% of the Patients. 89% of the ...

  • GlobeNewswire2 months ago

    Protalix BioTherapeutics Announces Poster Presentation on Baseline Characteristics for Fabry Disease Patients Screened in the Phase III BALANCE Study of Pegunigalsidase Alfa at the 55th ERA-EDTA Congress

    GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that a poster presentation on the characteristics of Fabry disease patients screened in the phase III BALANCE clinical trial of pegunigalsidase alfa, a PEGylated alfa galactosidase alfa enzyme, or PRX-102, for the treatment of Fabry disease was presented at the 55th ERA-EDTA Congress (European Renal Association – European Dialysis and Transplant Association).

  • GlobeNewswire2 months ago

    Protalix Announces Exchange and Discharge of Remaining 2018 Notes

    Protalix BioTherapeutics, Inc. (the “Company”) (NYSE American:PLX) (PLX.TA) announced today that $3.42 million of the aggregate principal amount of the Company’s outstanding 4.5% Convertible Senior Notes due 2018 (the “Notes”) will be exchanged for 2,613,636 shares of the Company’s common stock and $2.27 million in cash.  Additionally, the Company announced today that it has delivered the necessary funds under the indenture governing the Notes to effectively discharge the remaining outstanding Notes.  Additional details regarding the exchange can be found in the Company’s Form 8-K to be filed with the Securities and Exchange Commission.

  • Associated Press2 months ago

    Protalix: 1Q Earnings Snapshot

    The Carmiel, Israel-based company said it had a loss of 6 cents per share. The drug developer posted revenue of $4.6 million in the period. The company's shares closed at 40 cents. A year ago, they were ...

  • GlobeNewswire2 months ago

    Protalix BioTherapeutics Reports 2018 First Quarter Results and Provides Corporate Update

    CARMIEL, Israel, May 09, 2018-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary ...

  • GlobeNewswire3 months ago

    Protalix BioTherapeutics to Hold First Quarter 2018 Financial Results and Corporate Update Conference Call on May 9, 2018

    CARMIEL, Israel, April 26, 2018-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its ...

  • Benzinga4 months ago

    Benzinga Pro's 5 Stock To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Athersys, Inc. (NASDAQ: ATHX ) stock gained more than ...

  • Protalix BioTherapeutics Inc (NYSEMKT:PLX): Are Analysts Optimistic?
    Simply Wall St.5 months ago

    Protalix BioTherapeutics Inc (NYSEMKT:PLX): Are Analysts Optimistic?

    Protalix BioTherapeutics Inc’s (AMEX:PLX): Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in IsraelRead More...

  • SmarterAnalyst7 months ago

    Company Update (NYSE:PLX): Protalix Biotherapeutics Inc Shares Fly 10% Following Impressive Phase II Interim Data in Ulcerative Colitis

    Protalix Biotherapeutics Inc (NYSE:PLX) stock is riding a nearly 10% gain this morning after the Israeli biotech firm unleashed positive interim data from its Phase II clinical study in ulcerative colitis (UC). The trial is investigating the company's oral anti-TNF drug OPRX-106, with data set loose from the first 14 patients who have completed the randomized, open label, two-arm study. A total of 24 patients were enrolled and randomized to receive 2 mg or 8 mg of OPRX-106, administered orally, once daily, for 8 weeks.  The first 14 patients have completed the study, and four patients are currently in treatment and follow-up.  The trial evaluated key efficacy endpoints including clinical response and remission utilizing the Mayo score, as well as safety and pharmacokinetics.

  • Protalix (PLX) Fabry Disease Candidate Gets Orphan Status
    Zacks7 months ago

    Protalix (PLX) Fabry Disease Candidate Gets Orphan Status

    Protalix BioTherapeutics's (PLX) pipeline candidate, PRX-102, gets orphan drug status in Europe which is being developed as a treatment for Fabry disease.

  • Company Update (NYSE:PLX): Protalix Biotherapeutics Inc Shares Vault Another 7% After PRX-102 Wins Orphan Drug Designation from European Commission
    SmarterAnalyst7 months ago

    Company Update (NYSE:PLX): Protalix Biotherapeutics Inc Shares Vault Another 7% After PRX-102 Wins Orphan Drug Designation from European Commission

    Protalix Biotherapeutics Inc (NYSE:PLX) shares had already been on a solid 3% bump yesterday and in pre-market trading have gone on to race up another close to 7% amid the news of an exciting victory: the Israeli pharma firm's Fabry disease asset PRX-102 gained favor from the European Commission by granting of an Orphan Drug Designation (ODD). Should this orphan drug designation be maintained when the Fabry disease candidate garners approval for marketing in the European Union (EU), this could translate to an advantage of ten years of market exclusivity for Protalix within the EU. For context, the company has designed its PRX-102 asset, or pegunigalsidase alfa, as a plant cell culture expressed, and a chemically modified version of the recombinant alpha-Galactosidase-A protein, aimed to treat Fabry disease that afflicts one person out of every 40,000.